{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:23:45Z","timestamp":1789662225048,"version":"4.0.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40264-026-01683-5","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:23:56Z","timestamp":1781263436000},"page":"1119-1133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analytic Misjudgment of Drug Safety Evidence and Causality: From the Prosecutor\u2019s Fallacy and Simpson\u2019s Paradox to Artificial Intelligence"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-4716","authenticated-orcid":false,"given":"Tarek A.","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Rochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1683_CR1","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1136\/bmj.319.7225.1618","volume":"319","author":"D Isaacs","year":"1999","unstructured":"Isaacs D, Fitzgerald D. Seven alternatives to evidence-based medicine. BMJ. 1999;319:1618. https:\/\/doi.org\/10.1136\/bmj.319.7225.1618.","journal-title":"BMJ"},{"issue":"34","key":"1683_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/lpr\/mgm003","volume":"5","author":"R Meester","year":"2007","unstructured":"Meester R, Collins M, Gill RD, van Lambalgen M. On the (ab)use of statistics in the legal case against the nurse Lucia de B. Law Probab Risk. 2007;5(34):233250. https:\/\/doi.org\/10.1093\/lpr\/mgm003.","journal-title":"Law Probab Risk"},{"key":"1683_CR3","unstructured":"Taylor K. The Prosecutor\u2019s Fallacy. Centre for Evidence-Based Medicine [Internet]. 2018. Available from: https:\/\/www.cebm.ox.ac.uk\/news\/views\/theprosecutorsfallacy. Accessed 2026 Mar 14."},{"key":"1683_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024a.1445998","volume":"4","author":"TA Hammad","year":"2024","unstructured":"Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Front Drug Saf Regul. 2024;4:1445998. https:\/\/doi.org\/10.3389\/fdsfr.2024a.1445998.","journal-title":"Front Drug Saf Regul"},{"issue":"9","key":"1683_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/aje\/kwu025","volume":"179","author":"D Westreich","year":"2014","unstructured":"Westreich D, Iliinsky N. Epidemiology visualized: the prosecutor\u2019s fallacy. Am J Epidemiol. 2014;179(9):1125\u20137. https:\/\/doi.org\/10.1093\/aje\/kwu025.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1683_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264021011423","volume":"45","author":"D Croteau","year":"2022","unstructured":"Croteau D, Pinnow E, Wu E, Mu\u00f1oz M, Bulatao I, Dal Pan G. Sources of evidence triggering and supporting safetyrelated labeling changes: a 10Year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug Administration. Drug Saf. 2022;45(2):169\u201380. https:\/\/doi.org\/10.1007\/s40264021011423. (Epub 2022 Feb 3).","journal-title":"Drug Saf"},{"issue":"12","key":"1683_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nrd4129","volume":"12","author":"HG Eichler","year":"2013","unstructured":"Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013;12(12):907\u201316. https:\/\/doi.org\/10.1038\/nrd4129. (Epub 2013 Nov 15).","journal-title":"Nat Rev Drug Discov"},{"key":"1683_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1193413","volume":"3","author":"TA Hammad","year":"2023","unstructured":"Hammad TA, Afsar S, McAvoy LB, Le Louet H. Aspects to consider in causality assessment of safety signals: broadening the thought process. Front Drug Saf Regul. 2023;3:1193413. https:\/\/doi.org\/10.3389\/fdsfr.2023.1193413.","journal-title":"Front Drug Saf Regul"},{"key":"1683_CR9","doi-asserted-by":"publisher","first-page":"1193413","DOI":"10.3389\/fdsfr.2023.1193413","volume":"3","author":"TA Hammad","year":"2023","unstructured":"Hammad TA, Afsar S, McAvoy LB, Le Louet H. Aspects to consider in causality assessment of safety signals: broadening the thought process. Front Drug Saf Regul. 2023;3:1193413. https:\/\/doi.org\/10.3389\/fdsfr.2023.1193413.","journal-title":"Front Drug Saf Regul."},{"issue":"24","key":"1683_CR10","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa1012952","volume":"364","author":"MM H\u00f5es","year":"2011","unstructured":"H\u00f5es MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1012952.","journal-title":"N Engl J Med"},{"issue":"2","key":"1683_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/cpt.70180","volume":"119","author":"C Khouri","year":"2026","unstructured":"Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, et al. The rising misuse of pharmacovigilance reporting systems: A threat to evidence-based medicine. Clin Pharmacol Ther. 2026;119(2):318\u201321. https:\/\/doi.org\/10.1002\/cpt.70180. (Epub 2025 Dec 21).","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1683_CR12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/0000201820073010000007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891\u20138. https:\/\/doi.org\/10.2165\/0000201820073010000007.","journal-title":"Drug Saf"},{"issue":"6","key":"1683_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1683_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1573353","volume":"16","author":"TA Hammad","year":"2025","unstructured":"Hammad TA, Naylor M, Ely DM, Davies S. Exploring the complexities of disproportionality analysis in pharmacovigilance: reflections on the READUSPV guideline and a call to action. Front Pharmacol. 2025;16:1573353. https:\/\/doi.org\/10.3389\/fphar.2025.1573353.","journal-title":"Front Pharmacol"},{"key":"1683_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.07.014","volume":"139","author":"C Khouri","year":"2021","unstructured":"Khouri C, Revol B, Lepelley M, Mouffak A, Bernardeau C, Salvo F, et al. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. J Clin Epidemiol. 2021;139:191198. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.07.014.","journal-title":"J Clin Epidemiol"},{"key":"1683_CR16","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1016\/j.jclinepi.2021.06.022","volume":"138","author":"A Mouffak","year":"2021","unstructured":"Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021;138:7379. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.06.022.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1683_CR17","doi-asserted-by":"publisher","first-page":"679688","DOI":"10.1007\/s4026402501524x","volume":"48","author":"C Bernardeau","year":"2025","unstructured":"Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, et al. Are causal statements reported in pharmacovigilance disproportionality analyses using individual case safety reports exaggerated in related citations? A meta-epidemiological study. Drug Saf. 2025;48(6):679688. https:\/\/doi.org\/10.1007\/s4026402501524x.","journal-title":"Drug Saf"},{"issue":"4","key":"1683_CR18","doi-asserted-by":"publisher","first-page":"403413","DOI":"10.1007\/s4026401706204","volume":"41","author":"BA Golomb","year":"2018","unstructured":"Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA\u2019s Adverse Event Reporting System. Drug Saf. 2018;41(4):403413. https:\/\/doi.org\/10.1007\/s4026401706204.","journal-title":"Drug Saf"},{"issue":"30","key":"1683_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026751","volume":"100","author":"MC Chang","year":"2021","unstructured":"Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2021;100(30):e26751. https:\/\/doi.org\/10.1097\/MD.0000000000026751.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"1683_CR20","doi-asserted-by":"publisher","first-page":"11081113","DOI":"10.1016\/j.numecd.2017.10.011","volume":"27","author":"A Perlman","year":"2017","unstructured":"Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodiumglucosecotransporter2 inhibitors: analysis of the FDA Adverse Event Report System Database. Nutr Metab Cardiovasc Dis. 2017;27(12):11081113. https:\/\/doi.org\/10.1016\/j.numecd.2017.10.011.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"1683_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble JM. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2023;89(2):431\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1683_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002983","volume":"16","author":"J Menne","year":"2019","unstructured":"Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal events in patients receiving SGLT2inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983. https:\/\/doi.org\/10.1371\/journal.pmed.1002983.","journal-title":"PLoS Med"},{"issue":"6","key":"1683_CR23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","volume":"79","author":"M Zhuo","year":"2022","unstructured":"Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E. SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J Kidney Dis. 2022;79(6):858-867.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.015.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1683_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07020326","volume":"164","author":"R Freedman","year":"2007","unstructured":"Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):1269. https:\/\/doi.org\/10.1176\/appi.ajp.2007.07020326.","journal-title":"Am J Psychiatry"},{"key":"1683_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07010173","volume":"164","author":"I Kohen","year":"2007","unstructured":"Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007;164:1269\u201370.","journal-title":"Am J Psychiatry"},{"key":"1683_CR26","unstructured":"Gever J. FDA panel: Chantix boxed warning should stay. MedPage Today, 2014. Available from: https:\/\/www.medpagetoday.com\/primarycare\/smoking\/48119. Accessed 2026 Mar 14."},{"issue":"10037","key":"1683_CR27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/S01406736(16)302720","volume":"387","author":"RM Anthenelli","year":"2016","unstructured":"Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507\u201320. https:\/\/doi.org\/10.1016\/S01406736(16)302720.","journal-title":"Lancet"},{"key":"1683_CR28","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings, 2016. Available from: https:\/\/www.fda.gov\/drugs\/drugsafetyandavailability\/fdadrugsafetycommunicationfdarevisesdescriptionmentalhealthsideeffectsstopsmoking. Accessed 2026 Mar 1]."},{"key":"1683_CR29","unstructured":"European Medicines Agency. Champix, INN-varenicline: procedural steps taken and scientific information after the authorization, 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/proceduralstepsafter\/champixeparproceduralstepstakenscientificinformationafterauthorisation_en.pdf. Accessed 2026 Mar 14."},{"issue":"1","key":"1683_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/00031305.2014.876829","volume":"68","author":"J Pearl","year":"2014","unstructured":"Pearl J. Understanding Simpson\u2019s paradox. Am Stat. 2014;68(1):8\u201313.","journal-title":"Am Stat"},{"issue":"7","key":"1683_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199608153350701","volume":"335","author":"F Grodstein","year":"1996","unstructured":"Grodstein F, Stampfer M, Manson J, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335(7):453\u201361. https:\/\/doi.org\/10.1056\/NEJM199608153350701.","journal-title":"N Engl J Med"},{"issue":"12","key":"1683_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.7326\/000348191331220001219000008","volume":"133","author":"F Grodstein","year":"2000","unstructured":"Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133(12):933\u201341. https:\/\/doi.org\/10.7326\/000348191331220001219000008.","journal-title":"Ann Intern Med"},{"key":"1683_CR33","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1161\/01.CIR.101.22.2572","volume":"101","author":"C Varas-Lorenzo","year":"2000","unstructured":"Varas-Lorenzo C, Garc\u00eda-Rodr\u00edguez LA, P\u00e9rez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. Circulation. 2000;101:2572\u20138. https:\/\/doi.org\/10.1161\/01.CIR.101.22.2572.","journal-title":"Circulation"},{"key":"1683_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S01972456(97)000780","volume":"19","author":"The Women\u2019s Health Initiative Study Group","year":"1998","unstructured":"The Women\u2019s Health Initiative Study Group. Design of the Women\u2019s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61\u2013109. https:\/\/doi.org\/10.1016\/S01972456(97)000780.","journal-title":"Control Clin Trials"},{"issue":"6","key":"1683_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa030808","volume":"349","author":"JE Manson","year":"2003","unstructured":"Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523\u201334. https:\/\/doi.org\/10.1056\/NEJMoa030808.","journal-title":"N Engl J Med"},{"key":"1683_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.0006341X.2005.454_1.x","volume":"61","author":"RL Prentice","year":"2005","unstructured":"Prentice RL, Pettinger M, Anderson G. Statistical issues arising in the Women\u2019s Health Initiative. Biometrics. 2005;61:899\u2013941. https:\/\/doi.org\/10.1111\/j.0006341X.2005.454_1.x.","journal-title":"Biometrics"},{"issue":"6","key":"1683_CR37","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766\u201379. https:\/\/doi.org\/10.1097\/EDE.0b013e3181875e61.","journal-title":"Epidemiology"},{"issue":"9671","key":"1683_CR38","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S01406736(09)60708X","volume":"373","author":"JP Vandenbroucke","year":"2009","unstructured":"Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet. 2009;373(9671):1233\u20135. https:\/\/doi.org\/10.1016\/S01406736(09)60708X.","journal-title":"Lancet"},{"issue":"21","key":"1683_CR39","doi-asserted-by":"publisher","first-page":"15201528","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):15201528. https:\/\/doi.org\/10.1056\/NEJM200011233432103.","journal-title":"N Engl J Med"},{"issue":"9458","key":"1683_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S01406736(05)178647","volume":"365","author":"DJ Graham","year":"2005","unstructured":"Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase2 selective and nonselective nonsteroidal anti-inflammatory drugs. Lancet. 2005;365(9458):475\u201381. https:\/\/doi.org\/10.1016\/S01406736(05)178647.","journal-title":"Lancet"},{"issue":"11","key":"1683_CR41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa050493. (Erratum in: N Engl J Med. 2006;355(2):221.).","journal-title":"N Engl J Med"},{"issue":"11","key":"1683_CR42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071\u201380. https:\/\/doi.org\/10.1056\/NEJMoa050405.","journal-title":"N Engl J Med"},{"issue":"4","key":"1683_CR43","doi-asserted-by":"publisher","first-page":"31521","DOI":"10.1002\/pds.1560","volume":"17","author":"TA Hammad","year":"2008","unstructured":"Hammad TA, Graham DJ, Staffa JA, Kornegay CJ, Dal Pan G. Onset of acute myocardial infarction after use of nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf. 2008;17(4):31521.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1683_CR44","unstructured":"U.S. Food and Drug Administration. Vioxx (rofecoxib) questions and answers [Internet]. Silver Spring: FDA; 2004. Available from: https:\/\/www.fda.gov\/drugs\/postmarketdrugsafetyinformationpatientsandproviders\/vioxxrofecoxibquestionsandanswers. cited 2026 Mar 14."},{"key":"1683_CR45","doi-asserted-by":"publisher","first-page":"1445998","DOI":"10.3389\/fdsfr.2024b.1445998","volume":"4","author":"TA Hammad","year":"2024","unstructured":"Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Front Drug Saf Regul. 2024;4:1445998. https:\/\/doi.org\/10.3389\/fdsfr.2024b.1445998.","journal-title":"Front Drug Saf Regul."},{"issue":"4","key":"1683_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/pgs20180188","volume":"20","author":"SE Legge","year":"2019","unstructured":"Legge SE, Walters JT. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics. 2019;20(4):279\u201390. https:\/\/doi.org\/10.2217\/pgs20180188.","journal-title":"Pharmacogenomics"},{"key":"1683_CR47","unstructured":"Centers for Disease Control and Prevention. Clinical considerations: myocarditis and pericarditis after receipt of COVID19 vaccines among adolescents and young adults [Internet]. Atlanta: CDC; 2023. Available from: https:\/\/www.cdc.gov\/vaccines\/covid19\/clinicalconsiderations\/myocarditis.html. Accessed 2026 Mar 14."},{"key":"1683_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4444","volume":"341","author":"J Green","year":"2010","unstructured":"Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444. https:\/\/doi.org\/10.1136\/bmj.c4444.","journal-title":"BMJ"},{"issue":"6","key":"1683_CR49","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2010.1098","volume":"304","author":"CR Cardwell","year":"2010","unstructured":"Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304(6):657\u201363. https:\/\/doi.org\/10.1001\/jama.2010.1098.","journal-title":"JAMA"},{"issue":"1","key":"1683_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.15744\/23489782.1.301","volume":"2","author":"AM Walker","year":"2014","unstructured":"Walker AM. Esophageal cancer and bisphosphonates. J Pharm Drug Dev. 2014;2(1):101. https:\/\/doi.org\/10.15744\/23489782.1.301.","journal-title":"J Pharm Drug Dev."},{"key":"1683_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n699","volume":"372","author":"J Wise","year":"2021","unstructured":"Wise J. Covid19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699. https:\/\/doi.org\/10.1136\/bmj.n699.","journal-title":"BMJ"},{"issue":"10","key":"1683_CR52","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"385","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov19 vaccination. N Engl J Med. 2021;385(10):2092\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa2104840.","journal-title":"N Engl J Med"},{"issue":"12","key":"1683_CR53","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.vaccine.2023.02.013","volume":"41","author":"M de Vries","year":"2023","unstructured":"de Vries M, Claassen L, Lambooij MS, Timen A. Did the temporary suspension of Vaxzveria vaccinations influence COVID19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands. Vaccine. 2023;41(12):1961\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.013.","journal-title":"Vaccine"},{"issue":"1","key":"1683_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1542\/peds.20090792","volume":"125","author":"CL Barry","year":"2010","unstructured":"Barry CL, Busch SH. News media coverage of FDA warnings on pediatric antidepressant use and suicidality. Pediatrics. 2010;125(1):88\u201395. https:\/\/doi.org\/10.1542\/peds.20090792.","journal-title":"Pediatrics"},{"issue":"2","key":"1683_CR55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/pds.1886","volume":"19","author":"CA Pamer","year":"2010","unstructured":"Pamer CA, Hammad TA, Wu YT, Kaplan S, Rochester G, Governale L, et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf. 2010;19(2):158\u201374. https:\/\/doi.org\/10.1002\/pds.1886.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1683_CR56","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","volume":"63","author":"TA Hammad","year":"2006","unstructured":"Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63:332\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"1683_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2880","volume":"339","author":"M Stone","year":"2009","unstructured":"Stone M, Laughren T, Jones L, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880. https:\/\/doi.org\/10.1136\/bmj.b2880.","journal-title":"BMJ"},{"key":"1683_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jdin.2023.05.004","volume":"12","author":"N Trepanowski","year":"2023","unstructured":"Trepanowski N, Grant-Kels JM. Social media dermatologic advice: dermatology without dermatologists. JAAD Int. 2023;12:101\u20132. https:\/\/doi.org\/10.1016\/j.jdin.2023.05.004.","journal-title":"JAAD Int"},{"key":"1683_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdin.2023.10.008","volume":"14","author":"M Hackley","year":"2024","unstructured":"Hackley M, Al-Bataineh D, Lipoff JB. Portrayal of mental health effects of isotretinoin on TikTok. JAAD Int. 2024;14:90\u20131. https:\/\/doi.org\/10.1016\/j.jdin.2023.10.008.","journal-title":"JAAD Int"},{"issue":"2","key":"1683_CR60","first-page":"e227","volume":"14","author":"J Cohen","year":"2007","unstructured":"Cohen J, Adams S, Patten S. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. Can J Clin Pharmacol. 2007;14(2):e227\u201333.","journal-title":"Can J Clin Pharmacol"},{"issue":"2","key":"1683_CR61","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaad.2022.10.031","volume":"88","author":"K Kridin","year":"2023","unstructured":"Kridin K, Ludwig RJ. Isotretinoin and the risk of psychiatric disturbances: a global study shedding new light on a debatable story. J Am Acad Dermatol. 2023;88(2):388\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2022.10.031.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1683_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.14732165.2010.00478.x","volume":"9","author":"E Uhlenhake","year":"2010","unstructured":"Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression: a retrospective examination. J Cosmet Dermatol. 2010;9(1):59\u201363. https:\/\/doi.org\/10.1111\/j.14732165.2010.00478.x.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"1683_CR63","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jaad.2020.02.040","volume":"83","author":"DV Samuels","year":"2020","unstructured":"Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: a meta-analytic review. J Am Acad Dermatol. 2020;83(2):532\u201341. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.040.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1683_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JPA Ioannidis","year":"2005","unstructured":"Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. https:\/\/doi.org\/10.1371\/journal.pmed.0020124.","journal-title":"PLoS Med"},{"issue":"1","key":"1683_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2307\/2531947","volume":"43","author":"SJ Pocock","year":"1987","unstructured":"Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. Biometrics. 1987;43(1):169\u201378. https:\/\/doi.org\/10.2307\/2531947.","journal-title":"Biometrics"},{"key":"1683_CR66","unstructured":"U.S. Food and Drug Administration. Adaptive design clinical trials for drugs and biologics: guidance for industry [Internet]. Silver Spring: FDA; 2019. Available from: https:\/\/www.fda.gov\/regulatoryinformation\/searchfdaguidancedocuments\/adaptivedesignclinicaltrialsdrugsandbiologicsguidanceindustry. Accessed 2026 Mar 14."},{"issue":"1","key":"1683_CR67","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.552","volume":"7","author":"JD Ciolino","year":"2023","unstructured":"Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Transl Sci. 2023;7(1):e124. https:\/\/doi.org\/10.1017\/cts.2023.552.","journal-title":"J Clin Transl Sci"},{"issue":"1","key":"1683_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/0000164819900100000010","volume":"1","author":"KJ Rothman","year":"1990","unstructured":"Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43\u20136. https:\/\/doi.org\/10.1097\/0000164819900100000010.","journal-title":"Epidemiology"},{"key":"1683_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed2023000783","volume":"3","author":"AL Boulesteix","year":"2024","unstructured":"Boulesteix AL, Hoffmann S. To adjust or not to adjust: it is not the tests performed that count, but how they are reported and interpreted. BMJ Med. 2024;3:e000783. https:\/\/doi.org\/10.1136\/bmjmed2023000783.","journal-title":"BMJ Med"},{"issue":"3","key":"1683_CR70","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/ije\/dyn064","volume":"37","author":"S Greenland","year":"2008","unstructured":"Greenland S. Multiple comparisons and association selection in general epidemiology. Int J Epidemiol. 2008;37(3):430\u20134. https:\/\/doi.org\/10.1093\/ije\/dyn064.","journal-title":"Int J Epidemiol"},{"key":"1683_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.111688","volume":"180","author":"R Hooper","year":"2025","unstructured":"Hooper R. To adjust, or not to adjust, for multiple comparisons. J Clin Epidemiol. 2025;180:111688. https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111688.","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"1683_CR72","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457\u201371. https:\/\/doi.org\/10.1056\/NEJMoa072761.","journal-title":"N Engl J Med"},{"key":"1683_CR73","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","volume":"300","author":"S Singh","year":"2008","unstructured":"Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439\u201350.","journal-title":"JAMA"},{"key":"1683_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S14733099(07)701093","volume":"7","author":"D Yahav","year":"2007","unstructured":"Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338\u201348. https:\/\/doi.org\/10.1016\/S14733099(07)701093.","journal-title":"Lancet Infect Dis"},{"key":"1683_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.jcp.0000203198.11453.95","volume":"26","author":"TA Hammad","year":"2006","unstructured":"Hammad TA, Laughren T, Racoosin J. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol. 2006;26:203\u20137. https:\/\/doi.org\/10.1097\/01.jcp.0000203198.11453.95.","journal-title":"J Clin Psychopharmacol"},{"key":"1683_CR76","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/1740774511419165","volume":"8","author":"TA Hammad","year":"2011","unstructured":"Hammad TA, Pinheiro SP, Neyarapally GA. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials. 2011;8:559\u201370. https:\/\/doi.org\/10.1177\/1740774511419165.","journal-title":"Clin Trials"},{"issue":"4","key":"1683_CR77","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jama.285.4.437","volume":"285","author":"JPA Ioannidis","year":"2001","unstructured":"Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437\u201343. https:\/\/doi.org\/10.1001\/jama.285.4.437.","journal-title":"JAMA"},{"key":"1683_CR78","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixedeffect vs random effects models for meta-analysis: 3 points to consider. Glob Spine J. 2022;12:1624\u20136. https:\/\/doi.org\/10.1177\/21925682221110527.","journal-title":"Glob Spine J"},{"key":"1683_CR79","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1740774513479467","volume":"10","author":"TA Hammad","year":"2013","unstructured":"Hammad TA, Neyarapally GA, Pinheiro SP, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment. Clin Trials. 2013;10:389\u201397. https:\/\/doi.org\/10.1177\/1740774513479467.","journal-title":"Clin Trials"},{"key":"1683_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i157","volume":"352","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JPA, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157. https:\/\/doi.org\/10.1136\/bmj.i157.","journal-title":"BMJ"},{"key":"1683_CR81","doi-asserted-by":"publisher","DOI":"10.56759\/lela7055","volume-title":"Evidence synthesis and meta-analysis for drug safety: report of CIOMS Working Group X","author":"CIOMS Working Group X","year":"2016","unstructured":"CIOMS Working Group X. Evidence synthesis and meta-analysis for drug safety: report of CIOMS Working Group X. Geneva: Council for International Organizations of Medical Sciences; 2016."},{"issue":"3","key":"1683_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.NAJ.0000312247.74422.53","volume":"108","author":"DS Aschenbrenner","year":"2008","unstructured":"Aschenbrenner DS. Early alerts: FDA begins safety reviews of an antibiotic and a smoking cessation drug. Am J Nurs. 2008;108(3):35. https:\/\/doi.org\/10.1097\/01.NAJ.0000312247.74422.53.","journal-title":"Am J Nurs"},{"issue":"4","key":"1683_CR83","doi-asserted-by":"publisher","first-page":"381389","DOI":"10.1086\/655131","volume":"51","author":"PW Kim","year":"2010","unstructured":"Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010;51(4):381389. https:\/\/doi.org\/10.1086\/655131.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1683_CR84","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1086\/597264","volume":"48","author":"TD Nguyen","year":"2009","unstructured":"Nguyen TD, Williams B, Trang E. Cefepime therapy and allcause mortality. Clin Infect Dis. 2009;48(7):902\u20134.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"1683_CR85","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543\u201354. https:\/\/doi.org\/10.1056\/NEJMoa0805800.","journal-title":"N Engl J Med"},{"key":"1683_CR86","doi-asserted-by":"publisher","first-page":"10971099","DOI":"10.1056\/NEJMp1008502","volume":"363","author":"TM Michele","year":"2010","unstructured":"Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium\u2014the FDA\u2019s conclusions. N Engl J Med. 2010;363:10971099. https:\/\/doi.org\/10.1056\/NEJMp1008502.","journal-title":"N Engl J Med"},{"issue":"7","key":"1683_CR87","doi-asserted-by":"publisher","first-page":"700","DOI":"10.18553\/jmcp.2018.24.7.700","volume":"24","author":"JM Major","year":"2018","unstructured":"Major JM, Zhou EH, Ding Y, Ly T, Li J, Pinheiro SP, et al. The effect of FDA drug safety communications on patterns of tiotropium dispensing: a U.S. health plan claims database study. J Manag Care Spec Pharm. 2018;24(7):700\u20139. https:\/\/doi.org\/10.18553\/jmcp.2018.24.7.700.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1683_CR88","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMp1010788","volume":"363","author":"J Woodcock","year":"2010","unstructured":"Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med. 2010;363(1):1489\u201391. https:\/\/doi.org\/10.1056\/NEJMp1010788.","journal-title":"N Engl J Med"},{"key":"1683_CR89","first-page":"125","volume":"63","author":"RL Morrow","year":"2010","unstructured":"Morrow RL, et al. Impact of rosiglitazone meta-analysis on prescribing of glucose-lowering medications. J Clin Epidemiol. 2010;63:125\u201332.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1683_CR90","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ahj.2013.05.004","volume":"166","author":"KW Mahaffey","year":"2013","unstructured":"Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166(2):240-249.e1. https:\/\/doi.org\/10.1016\/j.ahj.2013.05.004.","journal-title":"Am Heart J"},{"key":"1683_CR91","unstructured":"Regan TL. FDA \u201cmea culpa\u201d part of a cautionary tale. Am J Manag Care. 2013;19(SP7):SP242\u2013SP243. Available from: https:\/\/www.ajmc.com\/view\/fda-mea-culpa-part-of-a-cautionary-tale."},{"key":"1683_CR92","volume-title":"Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII","author":"Council for International Organizations of Medical Sciences","year":"2010","unstructured":"Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII. Geneva: CIOMS; 2010."},{"key":"1683_CR93","unstructured":"European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): Module IX. Signal management (Rev. 1). London: European Medicines Agency; 2017. EMA\/827661\/2011 Rev. 1. Available from: European Medicines Agency. Not applicable."},{"issue":"2","key":"1683_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2023.100743","volume":"12","author":"A Bate","year":"2023","unstructured":"Bate A, Stegmann JU. Artificial intelligence and pharmacovigilance: what is happening, what could happen and what should happen? Health Policy Technol. 2023;12(2):100743. https:\/\/doi.org\/10.1016\/j.hlpt.2023.100743.","journal-title":"Health Policy Technol"},{"issue":"4","key":"1683_CR95","doi-asserted-by":"publisher","first-page":"359365","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1683_CR96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41746024010602","volume":"7","author":"M van der Schaar","year":"2024","unstructured":"van der Schaar M, Alaa AM, Floto A, et al. Revolutionizing clinical trials: a manifesto for AI-driven transformation. npj Digit Med. 2024;7:33. https:\/\/doi.org\/10.1038\/s41746024010602.","journal-title":"npj Digit Med."},{"issue":"3","key":"1683_CR97","doi-asserted-by":"publisher","first-page":"504512","DOI":"10.1111\/jep.13542","volume":"27","author":"F De Pretis","year":"2021","unstructured":"De Pretis F, Landes J, Peden W. Artificial intelligence methods for a Bayesian epistemology-powered evidence evaluation. J Eval Clin Pract. 2021;27(3):504512. https:\/\/doi.org\/10.1111\/jep.13542.","journal-title":"J Eval Clin Pract"},{"issue":"6","key":"1683_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253057","volume":"16","author":"F De Pretis","year":"2021","unstructured":"De Pretis F, Landes J. EA3: a softmax algorithm for evidence appraisal aggregation. PLoS ONE. 2021;16(6):e0253057. https:\/\/doi.org\/10.1371\/journal.pone.0253057.","journal-title":"PLoS ONE"},{"issue":"6","key":"1683_CR99","doi-asserted-by":"publisher","first-page":"473481","DOI":"10.1016\/j.tips.2022.03.009","volume":"43","author":"F De Pretis","year":"2022","unstructured":"De Pretis F, van Gils M, Forsberg MM. A smart hospital-driven approach to precision pharmacovigilance. Trends Pharmacol Sci. 2022;43(6):473481. https:\/\/doi.org\/10.1016\/j.tips.2022.03.009.","journal-title":"Trends Pharmacol Sci"},{"key":"1683_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2025.1678074","volume":"5","author":"P Chhikara","year":"2025","unstructured":"Chhikara P, Hammad TA. Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights. Front Drug Saf Regul. 2025;5:1678074. https:\/\/doi.org\/10.3389\/fdsfr.2025.1678074.","journal-title":"Front Drug Saf Regul"},{"key":"1683_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/d41586026006974","author":"M Basu","year":"2026","unstructured":"Basu M. Dozens of AI disease-prediction models were trained on dubious data. Nature. 2026. https:\/\/doi.org\/10.1038\/d41586026006974.","journal-title":"Nature"},{"issue":"1","key":"1683_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104593","volume":"31","author":"DISRUPTDS Industry Roundtable","year":"2026","unstructured":"DISRUPTDS Industry Roundtable. Generative AI in pharmaceutical R&D: from large language models to AI agents to regulation. Drug Discov Today. 2026;31(1):104593. https:\/\/doi.org\/10.1016\/j.drudis.2025.104593. (Epub 2026 Jan 8).","journal-title":"Drug Discov Today"},{"issue":"2","key":"1683_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/j.15396053.2008.00033.x","volume":"8","author":"G Gigerenzer","year":"2007","unstructured":"Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. Psychol Sci Public Interest. 2007;8(2):5396. https:\/\/doi.org\/10.1111\/j.15396053.2008.00033.x.","journal-title":"Psychol Sci Public Interest"},{"key":"1683_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s40290025005965","author":"BA Hendrickson","year":"2025","unstructured":"Hendrickson BA, McShea C, Hammad TA, et al. Publicly available clinical trial safety data: review and a call for standardization and improved reporting practices. Pharm Med. 2025. https:\/\/doi.org\/10.1007\/s40290025005965.","journal-title":"Pharm Med"},{"issue":"3","key":"1683_CR105","doi-asserted-by":"publisher","DOI":"10.1177\/1529100612451018","volume":"13","author":"S Lewandowsky","year":"2012","unstructured":"Lewandowsky S, Ecker UKH, Seifert CM, Schwarz N, Cook J. Misinformation and its correction: continued influence and successful debiasing. Psychol Sci Public Interest. 2012;13(3):106131. https:\/\/doi.org\/10.1177\/1529100612451018.","journal-title":"Psychol Sci Public Interest"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01683-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01683-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01683-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:12:13Z","timestamp":1788959533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01683-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1683"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01683-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TH and JR are employed by Takeda Pharmaceuticals and own stock. No other competing interests to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not involve human subject research, patient data, or clinical interventions.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article because no datasets were generated or analyzed for this paper. All information supporting the arguments in this article is contained within the paper and its references.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TH conceived the manuscript. Both authors contributed to the writing, revision, and editing of the manuscript and approved the final version.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this publication are solely those of the authors and do not necessarily represent the views of, or imply endorsement by, their employer.","order":8,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}]}}